ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP11

Lived Experience in Action: How Co-Creating a Psoriatic Arthritis Project Empowered My Journey as a Patient Advocate

Kathleen Gallant

Meeting: ACR Convergence 2025

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (PP09-PP13) Patient Perspectives

Session Type: Patient Perspectives

Session Time: 8:45AM-9:00AM

Background/Purpose: I am a person living with Psoriatic Arthritis (PsA) since the age of 20. I have spent decades working in advocacy. On my ‘good days,’ I focus on outreach to change national health policy. I have participated in various advisory boards, most recently in the GoodCare Campaign for PsA, a global, patient-driven project to address unmet needs in the PsA community.  Having experienced the challenges patients face—misdiagnosis, delayed treatment, lack of awareness, and isolation,  has motivated me to contribute to initiatives that bridge the gap between lived experience and clinical care.

Intervention: The GoodCare Campaign for PsA project was launched by the International Federation of Psoriasis Associations (IFPA) in 2022 to raise awareness of the need for PsA treatment guidelines and their integration into care pathways. I served on the steering committee helping to ensure that the patient voice remained central. Together with patients, clinicians and member associations, we co-created tools like the lived-experience illustration booklets, webinars, podcasts, social media materials, communication guides and a downloadable “treat-to-target” patient checklist. These resources support early symptom recognition and help patients, and their loved ones, navigate conversations with healthcare providers. Materials were translated into 9 languages and shared in global campaigns such as World Psoriasis Day, World Arthritis Day, and at international congresses including the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR).

Maintenance: Since its launch, the project has achieved measurable reach. The resources were shared globally via live podcasts recorded at major congresses reaching listeners in over 25 countries. A global survey conducted by IFPA showed over 50% of organizations advocating for people living with PsA had received and used the co-created materials – especially in under-resourced areas. Many, including myself, have emphasized the need for culturally adaptable formats to make the content inclusive. A key outcome was an engaging webinar with a rheumatologist exploring how treatment guidelines can be used as patient education tools.

Quality of Life: Co-leading this project has been personally empowering. Seeing patient insights transformed into tools and educational content gives me hope. Knowing my peers feel less alone has deepened my resilience and commitment, furthermore, sharing tailored resources with the medical community and advocating for shared decision-making is impactful. Among the many meaningful conversations I have been part of, one that stands out is this: Importance of shared decision making around therapeutic choice

Takeaway: This project shows the power of patient-physician collaboration.  I encourage patient leaders and healthcare professionals to adopt co-creation models, use shared decision-making tools and embrace communication strategies that work for both. This will not just change clinical outcomes—it changes lives.


Disclosures: K. Gallant: None

To cite this abstract in AMA style:

Gallant K. Lived Experience in Action: How Co-Creating a Psoriatic Arthritis Project Empowered My Journey as a Patient Advocate [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/lived-experience-in-action-how-co-creating-a-psoriatic-arthritis-project-empowered-my-journey-as-a-patient-advocate/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lived-experience-in-action-how-co-creating-a-psoriatic-arthritis-project-empowered-my-journey-as-a-patient-advocate/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology